Dianthus Therapeutics, Inc. $DNTH Stock Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA increased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 86.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 462,290 shares of the company’s stock after acquiring an additional 214,995 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.84% of Dianthus Therapeutics worth $40,705,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. ABS Investment Management LLC purchased a new position in shares of Dianthus Therapeutics during the 2nd quarter worth $194,960,000. EFG International AG acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth $49,000. GAMMA Investing LLC boosted its holdings in shares of Dianthus Therapeutics by 83.6% during the third quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock worth $49,000 after purchasing an additional 254 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in shares of Dianthus Therapeutics in the second quarter valued at $93,000. Finally, Nisa Investment Advisors LLC grew its position in shares of Dianthus Therapeutics by 75.0% in the third quarter. Nisa Investment Advisors LLC now owns 1,057 shares of the company’s stock valued at $93,000 after purchasing an additional 453 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Down 1.3%

DNTH stock opened at $88.81 on Wednesday. The company has a market cap of $5.00 billion, a price-to-earnings ratio of -22.26 and a beta of 1.47. The business has a fifty day simple moving average of $89.39 and a 200-day simple moving average of $85.96. Dianthus Therapeutics, Inc. has a 52 week low of $34.29 and a 52 week high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.13. The firm had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $0.46 million. Dianthus Therapeutics had a negative return on equity of 19.68% and a negative net margin of 7,436.50%. As a group, analysts expect that Dianthus Therapeutics, Inc. will post -3.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Roth Capital began coverage on Dianthus Therapeutics in a research note on Tuesday, October 27th. They issued a “buy” rating and a $113.00 target price for the company. JPMorgan Chase & Co. started coverage on Dianthus Therapeutics in a research note on Friday, September 11th. They issued an “overweight” rating and a $135.00 price target on the stock. Wedbush lifted their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Citigroup initiated coverage on Dianthus Therapeutics in a report on Friday, September 4th. They issued a “buy” rating and a $156.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $158.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Dianthus Therapeutics currently has an average rating of “Buy” and a consensus target price of $128.77.

Dianthus Therapeutics News Summary

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS estimates for 2026–2028, reflecting smaller projected losses, and reiterated a Buy rating with a $158 price target. The revised estimates could support investor optimism, though they are forecasts rather than company results. MarketBeat analyst estimates
• Positive Sentiment: A Zacks article cited analyst price targets implying 61.2% upside and noted that rising earnings estimates can be a positive signal, while also cautioning that price-target data has limited predictive value. Zacks article
• Neutral Sentiment: A report said short interest was zero shares as of November 10, despite describing it as a large increase. That inconsistency makes the figure difficult to interpret as a meaningful trading signal.
• Negative Sentiment: A Yahoo Finance article said DNTH may look stretched even as pipeline progress draws attention, which could temper enthusiasm after the stock’s strong run. Yahoo Finance article
• Negative Sentiment: HC Wainwright sharply cut its FY2029 EPS forecast from a small loss to a larger loss, and reduced its FY2030 estimate from $10.75 to $2.35 per share. Those longer-term revisions offset some of the improved nearer-term outlook. MarketBeat analyst estimates

Insider Buying and Selling

In related news, Director Simon Read sold 2,778 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total transaction of $326,553.90. Following the completion of the sale, the director owned 2,778 shares of the company’s stock, valued at approximately $326,553.90. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Edward Carr sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $101.38, for a total transaction of $2,027,600.00. Following the completion of the transaction, the chief accounting officer owned 20,000 shares in the company, valued at $2,027,600. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 45,902 shares of company stock valued at $4,814,779. 3.02% of the stock is currently owned by corporate insiders.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.